By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for Miebo (perfluorohexyloctane). Licensed from German firm Novaliq GmbH in 2019, Miebo is a first-in-class semifluorinated alkane indicated for the treatment of dry eye disease (DED) associated with meibomian gland dysfunction (MGD).
Mechanism of Action
Miebo is a clear, colorless eye drop solution composed of 100% perfluorohexyloctane. It rapidly spreads across the ocular surface and interacts with the lipid layer of the tear film to stabilize it and prevent excessive evaporation. The solution also penetrates the meibomian glands, dissolving viscous secretions and improving gland function. This dual action addresses the root cause of MGD-related dry eye.
Global Rights and FDA Approval
Novaliq previously granted Bausch + Lomb exclusive rights to develop and commercialize Miebo in the U.S. The FDA approved the product in May 2023 for treating both signs and symptoms of dry eye disease.-Fineline Info & Tech